US OptionsDetailed Quotes
SDGR250117C85000
- 0.15
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
0.15Open0.15Pre Close0 Volume23 Open Interest85.00Strike Price0.00Turnover625.19%IV341.42%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.0356Delta0.0059Gamma128.60Leverage Ratio-0.0934Theta0.0001Rho4.57Eff Leverage0.0017Vega
Schrodinger Stock Discussion
Sign in to post a comment
$Schrodinger (SDGR.US)$
Schrödinger Reports Third Quarter 2024 Financial Results
Schrödinger (SDGR) reported Q3 2024 financial results with total revenue of $35.3 million, down from $42.6 million in Q3 2023. Software revenue increased 10% to $31.9 million, while drug discovery revenue decreased to $3.4 million. The company announced a new collaboration with Novartis, receiving $150 million upfront with potential milestone payments up to $2.3 billion. Operating expenses rose to $86.2 millio...
Schrödinger Reports Third Quarter 2024 Financial Results
Schrödinger (SDGR) reported Q3 2024 financial results with total revenue of $35.3 million, down from $42.6 million in Q3 2023. Software revenue increased 10% to $31.9 million, while drug discovery revenue decreased to $3.4 million. The company announced a new collaboration with Novartis, receiving $150 million upfront with potential milestone payments up to $2.3 billion. Operating expenses rose to $86.2 millio...
$Schrodinger (SDGR.US)$
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
Schrödinger to receive $150 million upfront and eligible to receive up to approximately $2.3 billion in milestone payments plus royalties
Expanded multi-year software agreement enables technology deployment at significant scale across Novartis's global research organization
Schrödinger to host third quarter 2024 financial results webcast today at 8:00 a.m. ET
Schröd...
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
Schrödinger to receive $150 million upfront and eligible to receive up to approximately $2.3 billion in milestone payments plus royalties
Expanded multi-year software agreement enables technology deployment at significant scale across Novartis's global research organization
Schrödinger to host third quarter 2024 financial results webcast today at 8:00 a.m. ET
Schröd...
$Schrodinger (SDGR.US)$
all informatics 15% up tomorrow will be SDGR
$Recursion Pharmaceuticals (RXRX.US)$
$Exscientia (Delisted) (EXAI.US)$
all informatics 15% up tomorrow will be SDGR
$Recursion Pharmaceuticals (RXRX.US)$
$Exscientia (Delisted) (EXAI.US)$
2
$NVIDIA (NVDA.US)$
another silent killer going to blast soon 28
$Schrodinger (SDGR.US)$ AI + Drug Discovery
another silent killer going to blast soon 28
$Schrodinger (SDGR.US)$ AI + Drug Discovery
3
No comment yet
QMengColdJoke : This is the the worst AI stock I have and I am still in loss. I know I’d better double down here but I just don’t have interest to do so
muzikarete OP QMengColdJoke : This is the worst stock only for you. Because you are still in loss, but I’m not. Think about yourself.
NYC-yolo muzikarete OP : sb